Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

KENILWORTH, N.J., April 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy will be presented at the European Association for the Study of the Liver (EASL) 43rd annual meeting in Milan, Italy, April 23-27. PEGINTRON combination therapy is a current standard of care in the treatment of chronic hepatitis C. A total of 36 data presentations, including nine oral presentations, highlighting Schering-Plough hepatitis medications will be presented at EASL 2008.

The IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimaL pegylated interferon therapy) study is the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON and REBETOL combination therapy vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination therapy,(1) as well as a lower dose of PEGINTRON plus REBETOL in an investigational combination regimen. Pegasys and Copegus were dosed in accordance with their approved U.S. labeling in this study of more than 3,000 U.S. genotype 1 patients. Results showed that sustained virologic response (SVR), the primary endpoint of the study, was similar for all three treatment regimens. The study also showed in a secondary endpoint that fewer patients treated with both PEGINTRON regimens relapsed after the end of treatment compared to those receiving Pegasys and Copegus.

Final results will be presented for the EPIC3 study, in which more than 2,000 hepatit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... , May 23, 2013  A recently published clinical ... Houston, Texas , demonstrates that 3D mammography ... cancer detection. The study, "Implementation of ... Study," was led by Stephen L. Rose ... of the American Journal of Roentgenology (AJR). ...
(Date:5/23/2013)... JERUSALEM , May 23, 2013  Hadasit Bio-Holdings ... portfolio of biotech companies, based on intellectual property ... Israel ,s foremost medical research center, ... Neurosciences Ltd., received significant funding from the Israeli ... Chief Scientist (OCS) to support product development and ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ... biopharmaceutical,company, announced today that preliminary findings from ... treatment with AVR118,appears to have clinical activity ... incisions or dermatologic,dermabrasion., The Phase II open ...
... -- More than 70 abstracts highlight VELCADE efficacy ... care --, CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ ... the market leading therapy with unsurpassed single-agent,efficacy for ... featured at the upcoming International Myeloma,Workshop (IMW) in ...
Cached Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
(Date:5/23/2013)... 2013 Over the past decade, the ... which has affected the Medical Group Practice Management ... regular hours, more young physicians are opting out of ... groups,” says IBISWorld industry analyst Anna Son. In addition, ... number of older physicians are selling their practices and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Vegas ... is pleased to announce all new vacation packages ... in coming to Las Vegas for this patriotic ... it is thanks to VegasHotelEscapes.com's new special pricing ... to state that it guarantees the lowest prices ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
Breaking Medicine News(10 mins):Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2
... Nov. 1 It is estimated more than two ... States, with about,one-in-six expected to get the disease at ... Society. Thankfully, new treatment,technologies are making surviving the disease ... and more Americans are too large to be treated,using ...
... Nov. 1 The Michael J. Fox,Foundation (MJFF) ... 2008 Target Validation effort. Under this annual program ... 2008 for projects designed to validate the,therapeutic potential ... possible pharmaceutical industry investment and clinical trials., ...
... discovered a novel mechanism to predict survival in older ... have significant implications for new treatment approaches. , For ... aromatase, an enzyme that naturally makes estrogen from another ... survival rates in women over 65 with Stage 1 ...
... do not necessarily have worse outcomes after liver transplantation. ... they fare just as well. These are the results ... Hepatology, a journal published by John Wiley & Sons ... of Liver Diseases (AASLD). The article is also available ...
... carbon nanotubes can be destroyed by non-invasive radio waves ... a research team led by scientists at The University ... University has shown in preclinical experiments. , In a ... journal Cancer, researchers show that the technique completely destroyed ...
... keeping good track of daily blood sugar levels, while ... -- Fewer American adults with diabetes are developing cardiovascular ... blood sugar levels, according to new U.S. government research ... and Prevention studies, published in the CDC,s weekly journal ...
Cached Medicine News:Health News:Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008 2Health News:Researchers discover new way to predict survival in older women with lung cancer 2Health News:Researchers discover new way to predict survival in older women with lung cancer 3Health News:No racial differences seen in outcomes after liver transplantation 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 3Health News:Adults With Diabetes Doing Better Prevention Job 2
The new Vascular ClearWay Irrigating PTFE Balloon Catheter is a revolutionary micro-porous PTFE balloon catheter designed for the removal of fresh, soft emboli and thrombi, and for intraluminal irrig...
... for every general surgery need. No matter ... the GO450/GO400 Omni-Flex™ General Retractor Systems give ... the best possible exposure in the simplest ... and the hinged extension arm, the GO450 ...
... gelatinase-associated lipocalin, lipocalin-2) is a new early ... renal failure with a >90% positive predictive ... urine, as early as 2 hours after ... diagnostic marker for acute renal failure. ,Quantitative ...
... Don't miss the sounds you ... lung, and other body sounds ... with the Littmann Model 3000., ... technology, up to 18 times ...
Medicine Products: